Join
Live feed
·
PRReleasevia Quantisnow
Filana Therapeutics Inc. logo

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

ByQuantisnow·Wall Street's wire, on your screen.
FLNA· Filana Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FLNA (Filana Therapeutics Inc.) and more on Quantisnow.